Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial
July 26, 2016Research and Development Celgene, Revlimid, lymphoma
Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
BMS names Fouad Namouni as new oncology development head
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Gilead lowers full-year guidance as sales and profits down in Q2
July 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results
Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
IBS-D treatment Truberzi receives positive opinion from CHMP
July 26, 2016Manufacturing and Production, Sales and Marketing Allergan, EU, Truberzi, diarrhoea. CHMP, irritable bowel syndrome
Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …
Darzalex receives breakthrough designation in multiple myeloma from FDA
July 26, 2016Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo
July 26, 2016Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t
AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …
CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment
July 25, 2016Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis
Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …
The ethical battle for the future of pharma
July 25, 2016Drug pricing, ethics in pharma
A battle is raging for the soul of the pharma industry and the stakes are high. Those companies seeking to …
MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use
July 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza
Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …
Flawed studies at Semler Research Centre calls for suspension of medicines, EMA recommends
July 25, 2016Manufacturing and Production, Sales and Marketing EMA, Novartis, Teva, manufacturing, semler
Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …
400 current and former employees join sexual discrimination lawsuit against MSD
July 25, 2016Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit
Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …
AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C
AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …
EU recommends PrEP in Gilead’s HIV prevention treatment
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention
Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …
Shire receives positive EU opinion for pancreatic cancer drug
July 25, 2016Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire
Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …
EMA recommends two new treatments for advanced kidney cancer
July 22, 2016Research and Development, Sales and Marketing EMA, Eisai, renal cell carcinoma
The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …
Valeant receives complete response letter from FDA on glaucoma drug
July 22, 2016Medical Communications, Sales and Marketing FDA, Glaucoma, Valeant
Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA rejecting their new drug application …
MSD faces delay in C. diff drug approval as FDA requests more data
July 22, 2016Medical Communications, Research and Development C diff, FDA, MSD, Merck
MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …
Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug
July 22, 2016Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001
Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan
July 22, 2016Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab
Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …
George Scangos to step down as Biogen CEO
July 21, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, George Scangos
In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
